ZFIN ID: ZDB-FISH-180814-1
Fish name: gz36Tg
Genotype: gz36Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by gz36Tg
Human Disease Conditions Citations
cholangiocarcinoma chemical treatment by environment: mifepristone Yan et al., 2017
hepatocellular carcinoma chemical treatment by environment: mifepristone Yan et al., 2017
GENE EXPRESSION
Gene expression in gz36Tg
RNA expression
Expressed Gene Structure Conditions Figures
tgfb1a chemical treatment by environment: mifepristone Fig. 3 from Yan et al., 2017
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab5-acta2 control Fig. 3 from Yan et al., 2017
ab1-hnf4a chemical treatment by environment: mifepristone Fig. 4Fig. 5 from Yan et al., 2017
Ab5-acta2 chemical treatment by environment: mifepristone Fig. 3 from Yan et al., 2017
Ab1-casp3 control Fig. 5Fig. 6 from Yan et al., 2017
zn-8 chemical treatment by environment: mifepristone Fig. 3 from Yan et al., 2017
Ab1-tgfb1a chemical treatment by environment: mifepristone Fig. 3 from Yan et al., 2017
ab1-hnf4a control Fig. 4Fig. 5 from Yan et al., 2017
Ab26-mapk control Fig. 4Fig. 5Fig. 6 from Yan et al., 2017
Ab8-smad2 chemical treatment by environment: mifepristone Fig. 6 from Yan et al., 2017
Ab12-smad2 chemical treatment by environment: mifepristone Fig. 4Fig. 5Fig. 6 from Yan et al., 2017
Ab1-krt18 control Fig. 3Fig. 5 from Yan et al., 2017
Ab1-krt18 chemical treatment by environment: mifepristone Fig. 3Fig. 5 from Yan et al., 2017
Ab5-pcna control Fig. 3Fig. 5 from Yan et al., 2017
zn-8 control Fig. 3 from Yan et al., 2017
Ab12-smad2 control Fig. 4Fig. 5Fig. 6 from Yan et al., 2017
Ab8-smad2 control Fig. 6 from Yan et al., 2017
Ab26-mapk chemical treatment by environment: mifepristone Fig. 4Fig. 5Fig. 6 from Yan et al., 2017
Ab5-pcna chemical treatment by environment: mifepristone Fig. 3Fig. 5 from Yan et al., 2017
Ab1-casp3 chemical treatment by environment: mifepristone Fig. 5Fig. 6 from Yan et al., 2017
Reporter gene expression
Expressed Gene Structure Conditions Figures
mCherry chemical treatment by environment: mifepristone Fig. 3 from Yan et al., 2017
PHENOTYPE
Phenotype in gz36Tg
Phenotype Conditions Figures
common bile duct hyperplastic, abnormal chemical treatment by environment: mifepristone Fig. 3 from Yan et al., 2017
common bile duct hyperplastic, ameliorated chemical treatment by environment: mifepristone, chemical treatment: U0126 Fig. 5 from Yan et al., 2017
common bile duct hyperplastic, ameliorated chemical treatment by environment: mifepristone, chemical treatment: 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Fig. 5 from Yan et al., 2017
common bile duct increased circumference, abnormal chemical treatment by environment: mifepristone Fig. 3 from Yan et al., 2017
common bile duct cell population proliferation increased occurrence, abnormal chemical treatment by environment: mifepristone Fig. 3 from Yan et al., 2017
hepatocyte ab26-mapk labeling amount, ameliorated chemical treatment by environment: mifepristone, chemical treatment: U0126 Fig. 5 from Yan et al., 2017
hepatocyte hyperplastic, abnormal chemical treatment by environment: mifepristone Fig. 3Fig. 5 from Yan et al., 2017
hepatocyte hyperplastic, abnormal chemical treatment by environment: mifepristone, chemical treatment: U0126 Fig. 5 from Yan et al., 2017
hepatocyte tgfb1a expression increased amount, abnormal chemical treatment by environment: mifepristone Fig. 3 from Yan et al., 2017
hepatocyte ab26-mapk labeling increased amount, abnormal chemical treatment by environment: mifepristone Fig. 4Fig. 5 from Yan et al., 2017
hepatocyte ab26-mapk labeling increased amount, abnormal chemical treatment by environment: mifepristone, chemical treatment: 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Fig. 5 from Yan et al., 2017
hepatocyte ab1-tgfb1a labeling increased amount, abnormal chemical treatment by environment: mifepristone Fig. 3 from Yan et al., 2017
hepatocyte Ab12-smad2 labeling increased amount, abnormal chemical treatment by environment: mifepristone, chemical treatment: U0126 Fig. 5 from Yan et al., 2017
hepatocyte Ab12-smad2 labeling increased amount, abnormal chemical treatment by environment: mifepristone Fig. 4 from Yan et al., 2017
hepatocyte mCherry expression increased amount, abnormal chemical treatment by environment: mifepristone Fig. 3 from Yan et al., 2017
liver ab1-casp3 labeling amount, ameliorated chemical treatment by environment: mifepristone, chemical treatment: 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Fig. 5 from Yan et al., 2017
liver ab5-pcna labeling amount, ameliorated chemical treatment by environment: mifepristone, chemical treatment: U0126 Fig. 5 from Yan et al., 2017
liver Ab12-smad2 labeling increased amount, abnormal chemical treatment by environment: mifepristone Fig. 6 from Yan et al., 2017
liver ab1-casp3 labeling increased amount, abnormal chemical treatment by environment: mifepristone, chemical treatment: U0126 Fig. 5 from Yan et al., 2017
liver Ab8-smad2 labeling increased amount, abnormal chemical treatment by environment: mifepristone Fig. 6 from Yan et al., 2017
liver ab1-casp3 labeling increased amount, abnormal chemical treatment by environment: mifepristone Fig. 5Fig. 6 from Yan et al., 2017
liver ab5-pcna labeling increased amount, abnormal chemical treatment by environment: mifepristone Fig. 5 from Yan et al., 2017
liver ab5-pcna labeling increased amount, abnormal chemical treatment by environment: mifepristone, chemical treatment: 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Fig. 5 from Yan et al., 2017
liver ab26-mapk labeling increased amount, abnormal chemical treatment by environment: mifepristone Fig. 6 from Yan et al., 2017
liver neoplastic, abnormal chemical treatment by environment: mifepristone Fig. 3Fig. 5 from Yan et al., 2017
liver neoplastic, ameliorated chemical treatment by environment: mifepristone, chemical treatment: U0126 Fig. 5 from Yan et al., 2017
liver cell death increased occurrence, abnormal chemical treatment by environment: mifepristone Fig. 5 from Yan et al., 2017
liver cell death increased occurrence, ameliorated chemical treatment by environment: mifepristone, chemical treatment: 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Fig. 5 from Yan et al., 2017
liver cell death increased occurrence, exacerbated chemical treatment by environment: mifepristone, chemical treatment: U0126 Fig. 5 from Yan et al., 2017
liver cell population proliferation increased occurrence, abnormal chemical treatment by environment: mifepristone Fig. 5 from Yan et al., 2017
liver cell population proliferation increased occurrence, ameliorated chemical treatment by environment: mifepristone, chemical treatment: U0126 Fig. 5 from Yan et al., 2017
liver cell population proliferation increased occurrence, exacerbated chemical treatment by environment: mifepristone, chemical treatment: 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Fig. 5 from Yan et al., 2017
liver cholangiocarcinoma increased amount, abnormal chemical treatment by environment: mifepristone Fig. 3Fig. 5 from Yan et al., 2017
liver cholangiocarcinoma increased amount, ameliorated chemical treatment by environment: mifepristone, chemical treatment: 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Fig. 5 from Yan et al., 2017
liver cholangiocarcinoma increased amount, ameliorated chemical treatment by environment: mifepristone, chemical treatment: U0126 Fig. 5 from Yan et al., 2017
liver cholangiocyte Ab12-smad2 labeling amount, ameliorated chemical treatment by environment: mifepristone, chemical treatment: 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Fig. 5 from Yan et al., 2017
liver cholangiocyte ab26-mapk labeling amount, ameliorated chemical treatment by environment: mifepristone, chemical treatment: U0126 Fig. 5 from Yan et al., 2017
liver cholangiocyte Ab12-smad2 labeling increased amount, abnormal chemical treatment by environment: mifepristone Fig. 5 from Yan et al., 2017
liver cholangiocyte ab26-mapk labeling increased amount, abnormal chemical treatment by environment: mifepristone Fig. 5 from Yan et al., 2017
liver cholangiocyte ab26-mapk labeling increased amount, abnormal chemical treatment by environment: mifepristone, chemical treatment: 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Fig. 5 from Yan et al., 2017
liver cholangiocyte Ab12-smad2 labeling increased amount, abnormal chemical treatment by environment: mifepristone, chemical treatment: U0126 Fig. 5 from Yan et al., 2017
liver hepatocellular adenoma increased amount, abnormal chemical treatment by environment: mifepristone Fig. 3Fig. 5 from Yan et al., 2017
liver hepatocellular carcinoma increased amount, abnormal chemical treatment by environment: mifepristone Fig. 3Fig. 5 from Yan et al., 2017
liver hepatocellular carcinoma increased amount, abnormal chemical treatment by environment: mifepristone, chemical treatment: 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Fig. 5 from Yan et al., 2017

CITATIONS  (1)